At the 2013 Cardiovascular Research Technologies (CRT) conference, peripheral arterial disease (PAD) experts presented on a broad range of novel techniques and devices transforming the treatment paradigm. With countless devices on the market geared to treat various forms of the disease, the list of physician preference items continues to grow, driving up device costs for hospitals.
Atherectomy devices: Expensive toys or imperative tools?
With 2013 in full swing, we’ve taken a step back to review the major CV technology stories of 2012. From devices gaining FDA approval to therapies demonstrating paradigm-shifting potential, 2012 was a year of significant innovation across CV services. To help CV leaders nationwide distill the most impactful new research, data, and FDA approvals, we’ve broken down the four top stories of 2012 and what you need to know in 2013.
Top cardiovascular technology trends of 2012
Gaithersburg, MD- On Wednesday, June 13, the FDA's Circulatory Systems Devices Panel voted to recommend the Edwards SAPIEN transcatheter aortic valve for clinical approval in high-risk surgical aortic valve replacement candidates. Since November of 2011, SAPIEN has been approved for use only in patients deemed inoperable. However, if the FDA opts to heed the panel's recommendation for approval, the patient population eligible for SAPIEN will expand considerably.
FDA panel recommends clinical approval of SAPIEN TAVR device for high risk surgical aortic valve replacement candidates